|
Cholesteatoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> The miRNA microarray technology showed totally 44 upregulated (miRNA-21-3p, miRNA-584-5p, miRNA-16-1-3p, etc) and 175 downregulated (miRNA-10a-5p, miRNA-152-5p, miRNA-203b-5p, etc) miRNAs in cholesteatoma tissues with 2-fold change compared with normal skin.
|
30443177 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-16-1 Inhibits Tumor Cell Proliferation and Induces Apoptosis in A549 Non-Small Cell Lung Carcinoma Cells.
|
27712591 |
2016 |
|
Epilepsy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miR-16-1 expression, heat shock protein 70 and inflammatory reactions in astrocytes of mice with epilepsy induced by encephalitis B virus infection.
|
28672958 |
2017 |
|
Encephalitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miR-16-1 expression, heat shock protein 70 and inflammatory reactions in astrocytes of mice with epilepsy induced by encephalitis B virus infection.
|
28672958 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-16-1 might be suggested to behave as a tumor suppressor in DLBCL in our study.
|
30552617 |
2019 |
|
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma.
|
31018244 |
2019 |
|
Osteosarcoma of bone
|
0.020 |
Biomarker
|
disease |
BEFREE |
MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma.
|
31018244 |
2019 |
|
Childhood Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma.
|
31018244 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Accordingly, relatively higher levels of miR-15a and miR-16-1 were found in M IGHV3-23 compared with M non-IGHV3-23 CLL.
|
20068100 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, we identified a novel variation in miR-16-1 that had not been described previously in CLL patients.
|
24306027 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
An association between CLL-associated chromosomal abnormalities and miRNA deregulation is beginning to emerge. miRNAs may play a biological role in the pathogenesis of CLL: specific miRNAs (miR-15a and miR-16-1) are located at a chromosomal region (13q14.3) that is often absent in patients with CLL.
|
21156224 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
An inverse correlation has been shown in B cell chronic lymphocytic leukemia (B-CLL) between miR-15a and miR-16-1 expression and the expression levels of arginyl-tRNA synthetase (RARS), an enzyme which associates with the cofactor p43 in the aminoacyl-tRNA synthetase complex.
|
15648093 |
2005 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
An inverse correlation has been shown in B cell chronic lymphocytic leukemia (B-CLL) between miR-15a and miR-16-1 expression and the expression levels of arginyl-tRNA synthetase (RARS), an enzyme which associates with the cofactor p43 in the aminoacyl-tRNA synthetase complex.
|
15648093 |
2005 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anillin is required for tumor growth and regulated by miR-15a/miR-16-1 in HBV-related hepatocellular carcinoma.
|
30103211 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both miR-15a and miR-16-1 contributes to inhibiting FASN expression and breast cancer cell proliferation.
|
27713175 |
2016 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both miR-15a and miR-16-1 contributes to inhibiting FASN expression and breast cancer cell proliferation.
|
27713175 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster).
|
17727326 |
2007 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
CCK-8, Annexin V/FITC (fluorescein isothiocyanate), wound healing, and transwell assays were used to evaluate the functions of miR-16-1 that involves cell proliferation, apoptosis, motility, and invasion.
|
23175429 |
2013 |
|
leukemia
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL) is the most common human leukemia and is characterized by predominantly nondividing malignant B cells overexpressing the antiapoptotic B cell lymphoma 2 (Bcl2) protein. miR-15a and miR-16-1 are deleted or down-regulated in the majority of CLLs.
|
16166262 |
2005 |
|
Childhood Leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL) is the most common human leukemia and is characterized by predominantly nondividing malignant B cells overexpressing the antiapoptotic B cell lymphoma 2 (Bcl2) protein. miR-15a and miR-16-1 are deleted or down-regulated in the majority of CLLs.
|
16166262 |
2005 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Conversely, miR-16-1 suppression affected NSCLC cell proliferation and apoptosis, and these protein expressions resulted in completely opposite impacts.
|
27712591 |
2016 |
|
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Conversely, reconstitution of miR-15a and miR-16-1 expression results in growth arrest, apoptosis and marked regression of prostate tumor xenografts.
|
18931683 |
2008 |
|
Nephroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cytoplasmic Localization of WT1 and Decrease of miRNA-16-1 in Nephrotic Syndrome.
|
28299339 |
2017 |
|
Nephrotic Syndrome
|
0.010 |
Biomarker
|
group |
BEFREE |
Cytoplasmic Localization of WT1 and Decrease of miRNA-16-1 in Nephrotic Syndrome.
|
28299339 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Downregulation of miR-15a and miR-16-1 correlated with higher Gleason score (P = 0.002 and P = 0.006, respectively), higher tumor stage (P = 0.001 and P = 0.01, respectively), PCa metastasis (P = 0.002 and P = 0.025, respectively) and lymph node involvement (P = 0.02 and P = 0.007, respectively).
|
29522280 |
2018 |